FOR IMMEDIATE RELEASE Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema Cincinnati, OH, February 13, 2014 – Aerpio Therapeutics, Inc., a clinical-stage b - Release factor - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-02-13 16:12:56 Vascular endothelial growth factor Ranibizumab Health Diabetic retinopathy Macular edema Genentech Retina Ophthalmology Medicine Angiology		FOR IMMEDIATE RELEASE Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema Cincinnati, OH, February 13, 2014 – Aerpio Therapeutics, Inc., a clinical-stage b Add to Reading List Source URL: www.aerpio.com Download Document from Source Website File Size: 284,97 KB Share Document on Facebook

	CMTF005 - Food is Medicine - Checklist_Debranded DocID: 1xVMk - View Document
	Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses Daniel Halperin† Thomas S. Heydt-Benjamin† DocID: 1xVge - View Document
	CMTF005 - Food is Medicine - Checklist_Debranded_with bleed DocID: 1xUza - View Document
	CMTF005 - Food is Medicine - Checklist_Debranded_edited DocID: 1xTtU - View Document
	PDF Document DocID: 1xSqy - View Document